Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Camurus AB ( (SE:CAMX) ) has issued an update.
Camurus reported a successful second quarter in 2025, with total revenues increasing by 52% to SEK 676 million and profit before tax soaring by 195% to SEK 307 million. The company maintained its financial outlook for 2025 and highlighted key achievements such as a collaboration with Eli Lilly and Company, European Commission’s marketing authorization for Oczyesa®, and positive Phase 2b results for CAM2029. These developments underscore Camurus’ strong market positioning and potential for growth, benefiting stakeholders and reinforcing its leadership in the biopharmaceutical industry.
The most recent analyst rating on (SE:CAMX) stock is a Buy with a SEK750.00 price target. To see the full list of analyst forecasts on Camurus AB stock, see the SE:CAMX Stock Forecast page.
More about Camurus AB
Camurus AB is an international biopharmaceutical company focused on developing and commercializing innovative long-acting medicines for severe and chronic diseases. Utilizing its proprietary FluidCrystal® technology, the company has a strong R&D pipeline targeting dependence, pain, cancer, and endocrine diseases. Camurus operates across Europe, the US, and Australia, with its headquarters in Lund, Sweden, and is listed on Nasdaq Stockholm under the ticker CAMX.
Average Trading Volume: 203,932
Current Market Cap: SEK40.96B
Find detailed analytics on CAMX stock on TipRanks’ Stock Analysis page.